Abeona Therapeutics Inc.
Pipeline4 assets
- prademagene zamikeracelpz-cel / ZEVASKYN / COL7A1 / autologous cell-based gene therapy / Dermatology / rare diseaserecessive dystrophic epidermolysis bullosa (RDEB)Approvedapproved
- PSMA SIR-TABO-701 / PSMA / engineered autologous T-cell therapy / OncologyAdvanced prostate cancerPreclinicalpreclinical
- UX111UX111 / SGSH / in vivo AAV9 gene therapy / Rare disease / CNSSanfilippo Syndrome Type A (MPS IIIA)Phase 3clinical
- TSHA-102TSHA-102 / MECP2 / intrathecal AAV9 gene transfer therapy / Rare disease / CNSRett SyndromePhase 1/2clinical
Latest news20 items
All newsAbeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced activation of the Children’s Hospital of Philadelphia (CHOP) as the sixth Qualified Treatment Center (QTC) for the administration of ZEVASKYN...
Abeona Therapeutics® Announces Date of First Quarter Financial Results
CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial results for the first quarter of 2026 and corporate progress. The conference call will be available via phone and webcast....
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4)....